LFA Lugano Financial Advisors SA Has $96,000 Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

LFA Lugano Financial Advisors SA increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 30.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,300 shares of the medical research company’s stock after buying an additional 300 shares during the quarter. LFA Lugano Financial Advisors SA’s holdings in Edwards Lifesciences were worth $96,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in EW. Wellington Management Group LLP raised its position in shares of Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. State Street Corp increased its holdings in Edwards Lifesciences by 1.0% during the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after purchasing an additional 256,538 shares in the last quarter. Geode Capital Management LLC raised its position in Edwards Lifesciences by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock valued at $889,050,000 after buying an additional 284,918 shares during the last quarter. Fisher Asset Management LLC raised its position in Edwards Lifesciences by 7.7% in the 4th quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock valued at $723,664,000 after buying an additional 696,965 shares during the last quarter. Finally, Jennison Associates LLC purchased a new position in Edwards Lifesciences during the 4th quarter worth $555,939,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.2 %

Shares of Edwards Lifesciences stock opened at $68.52 on Thursday. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a 50 day simple moving average of $71.92 and a two-hundred day simple moving average of $70.34. The firm has a market cap of $40.28 billion, a PE ratio of 9.83, a PEG ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the sale, the chief executive officer now owns 59,083 shares of the company’s stock, valued at approximately $4,106,859.33. This trade represents a 9.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the sale, the vice president now owns 22,588 shares of the company’s stock, valued at $1,569,414.24. The trade was a 1.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 44,303 shares of company stock valued at $3,255,356. Insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on EW shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Citigroup lifted their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their target price for the company from $82.00 to $90.00 in a report on Monday, December 16th. Morgan Stanley lifted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. Finally, Truist Financial restated a “hold” rating and issued a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.